Thunen Shelley B
SEC CIK 1297491 · EDGAR
BoughtSold
Most active insiders at AEON, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LYNCH TIMOTHY P | 10% | $243.5K | — |
| 2 | Bancroft Robert E. | Pres, CEO, Dir | — | — |
| 3 | Sy Jennifer | PRINCIPAL ACCOUNTING Off | — | — |
| 4 | Wilson Alexander Blair | CLO, CSO, Corp Sec | — | — |
| 5 | Oh Chad | Chief MEDICAL Off | — | — |
| 6 | Forth Marc | Dir | — | — |
| 7 | Bencich John | CFO | — | — |
| 8 | Carter Eric G | Dir | — | — |
| 9 | FISCHER JOST | Dir | — | — |
| 10 | Thunen Shelley B | Dir | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-22 18:22 | 2026-06-17 | AEON | AEON Biopharma, Inc. | Thunen Shelley B | Dir | A - Grant | $0.00 | +222.7K | 258.7K | +618% | $0 | |
| D | 2025-04-15 | 2025-04-14 | RXST | RxSight, Inc. | Thunen Shelley B | See remarks | M - OptEx | $4.34 | +7,792 | 38.4K | +25% | +$33.8K |
| DMT | 2024-10-02 | 2024-10-01 | RXST | RxSight, Inc. | Thunen Shelley B | See remarks | S - Sale+OE | $48.45 | -15.0K | 40.2K | -27% | -$726.8K |
| DT | 2024-10-02 | 2024-10-01 | RXST | RxSight, Inc. | Thunen Shelley B | See remarks | M - OptEx | $16.00 | +15.0K | 45.4K | +49% | +$240.0K |
| D | 2024-09-04 | 2024-08-31 | AEON | AEON Biopharma, Inc. | Thunen Shelley B | Dir | A - Grant | $0.00 | +36.0K | 36.0K | New | $0 |
| D | 2024-07-16 | 2024-07-15 | RXST | RxSight, Inc. | Thunen Shelley B | See remarks | M - OptEx | $4.34 | +16.5K | 30.4K | +118% | +$71.6K |
| DMT | 2024-07-02 | 2024-07-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $58.61 | -10.0K | 13.9K | -42% | -$586.1K |
| DMTI | 2024-07-02 | 2024-07-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $58.77 | -8,402 | 0 | -100% | -$493.8K |
| DT | 2024-07-02 | 2024-07-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | M - OptEx | $15.60 | +10.0K | 23.9K | +72% | +$156.0K |
| DT | 2024-05-02 | 2024-05-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | M - OptEx | $15.60 | +10.2K | 23.9K | +75% | +$159.9K |
| DMT | 2024-05-02 | 2024-05-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $52.69 | -10.0K | 13.9K | -42% | -$526.9K |
| MTI | 2024-04-02 | 2024-04-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale | $49.89 | -20.0K | 19.5K | -51% | -$997.9K |
| DT | 2024-03-05 | 2024-03-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | M - OptEx | $15.60 | +10.0K | 23.7K | +73% | +$156.0K |
| DMT | 2024-03-05 | 2024-03-01 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $56.37 | -10.0K | 13.7K | -42% | -$563.7K |
| DM | 2024-02-07 | 2024-02-05+ | RXST | RxSight, Inc. | Thunen Shelley B | CFO | M - OptEx | $12.66 | +31.9K | 29.6K | New | +$403.7K |
| DM | 2024-02-07 | 2024-02-05+ | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $47.31 | -25.0K | 13.7K | -65% | -$1.18M |
| DM | 2024-01-29 | 2024-01-26 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | M - OptEx | $13.75 | +36.3K | 38.6K | +1,583% | +$498.7K |
| D | 2024-01-29 | 2024-01-26 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $47.11 | -31.8K | 6,791 | -82% | -$1.50M |
| DMT | 2024-01-03 | 2024-01-02 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $39.24 | -10.0K | 7,772 | -56% | -$392.4K |
| DT | 2024-01-03 | 2024-01-02 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | M - OptEx | $15.60 | +10.0K | 12.3K | +436% | +$156.0K |
| D | 2023-12-18 | 2023-12-15 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | M - OptEx | $15.60 | +20.0K | 22.3K | +873% | +$312.0K |
| DMI | 2023-12-18 | 2023-12-15 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $39.31 | -20.0K | 38.4K | -34% | -$786.3K |
| D | 2023-12-18 | 2023-12-15 | RXST | RxSight, Inc. | Thunen Shelley B | CFO | S - Sale+OE | $39.35 | -20.0K | 2,291 | -90% | -$787.0K |
Purchase Sale Sale after option exercise All abbreviations